Category: Publications

Search News
Categories
Archives
Metal analysis of urine for pancreatic cancer detection

28th April 2020

Research has revealed that the signature of metal ions present in urine samples is an accurate indicator of pancreatic ductal adenocarcinoma, one of the deadliest types of cancer.

Read more

The TME: Key to controlling cancer cell growth

10th March 2020

The tumour microenvironment: Key to controlling cancer cell growth Research led by Barts Cancer Institute (BCI), Queen Mary University of London, reveals novel insights into the role of the tumour […]

Read more

New and valuable insights into familial myeloid leukaemia

3rd March 2020

Research has identified new genetic features implicated in a type of blood cancer known as familial myeloid leukaemia. The study, published in Nature Communications, offers novel insights into the biology of this inherited cancer, and provides a framework to inform how to more effectively manage at-risk individuals and patients affected by this type of blood malignancy.

Read more

Immune therapy reduces risk of recurrence in aggressive breast cancer

27th February 2020

An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of Barts Cancer Institute, Queen Mary University of London.

Read more

Foot-and-mouth-disease virus could help target pancreatic cancer

12th February 2020

Researchers at Barts Cancer Institute, Queen Mary University of London, have identified a peptide, or protein fragment, taken from the foot-and-mouth-disease virus that targets another protein, called avβ6 (alpha-v-beta-6). This protein is found at high levels on the surface of the majority of pancreatic cancer cells.

Read more

Mouse models of ovarian cancer

27th January 2020

Research led by the Barts Cancer Institute, Queen Mary University of London, has revealed that mouse models of the most common and deadly form of ovarian cancer, high-grade serous ovarian cancer, can effectively replicate the disease in humans. These models provide useful pre-clinical tools that may help to determine which patients are likely to respond to particular treatments.

Read more

Search News
Categories
Archives